|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Gates Malaria Partnership |
|---|---|
| Information provided by: | Gates Malaria Partnership |
| ClinicalTrials.gov Identifier: | NCT00169078 |
Purpose
Attempts to understand the relationship malaria transmission intensity and antimalarial drug resistance had rested mainly on mathematical models. To date, except for two studies which reported reductions in the prevalence of drug resistance in Tanzania and Zimbabwe, no other field data addressed the impact of reducing malaria transmission by the use of vector control measures on antimalarial drug resistance. Thus whether vector control decrease or increase drug resistance remains a contentious issue. The aim of this study was to investigate the impact of insecticide-treated curtains (ITCs) on clinical and parasitological outcomes in children with uncomplicated malaria treated with chloroquine (CQ), on the prevalence of genetic markers of resistance to CQ and sulphadoxine-pyrimethamine (SP) and on the ability of children to clear drug resistant parasites. The therapeutic efficacy of CQ was studied in 9 villages which used ITCs for 6-8 years and 9 villages with no history of ITC use. A cross-sectional survey was also conducted to estimate the prevalence of genetic markers of resistance to CQ and SP in asymptomatic children.
| Condition | Intervention |
|---|---|
|
Malaria |
Drug: Chloroquine |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
| Official Title: | A Study of the Impact of Insecticide-Treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso |
| Estimated Enrollment: | 1035 |
| Study Start Date: | July 2002 |
| Estimated Study Completion Date: | December 2002 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 6 Months to 59 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age between 6 and 59 months Mono infection with P.falciparum malaria, with parasitaemia in the range of 1,000 to 150,000 parasites per ml Absence of danger signs or signs of severe malaria. Axillary temperature >= 37.5 ºC. Absence of signs of severe malnutrition. Absence of any obvious cause of fever other than malaria. No history of allergy to CQ. Willingness to return to the health facility for follow-up. Informed consent obtained from the caretaker of the child
Exclusion Criteria:
Danger signs of severe or complicated malaria, persisted vomiting. Received treatment with an antimalarial drug other than CQ in the last 2 weeks. Caretaker did not sign the consent form
Contacts and Locations| Burkina Faso, Kadiogo | |
| Centre National de Recherche et de Formation sur le Paludisme | |
| Ouagadougou, Kadiogo, Burkina Faso, 2208 | |
| Principal Investigator: | Simon Cousens, PhD | London School of Hygiene and Tropical Medicine |
| Principal Investigator: | Brian M Greenwood, FRCP FRS | London School of Hygiene and Tropical Medicine |
| Principal Investigator: | Diadier Diallo, MsC | Centre National de Recherche et de Formation sur le Paludisme |
| Principal Investigator: | Colin Sutherland, PhD | London School of Hygiene and Tropical Medicine |
More Information
| Study ID Numbers: | ITCR5093 |
| Study First Received: | September 9, 2005 |
| Last Updated: | September 9, 2005 |
| ClinicalTrials.gov Identifier: | NCT00169078 History of Changes |
| Health Authority: | United Kingdom: Research Ethics Committee |
|
Transmission intensity Insecticide-treated materials antimalarial drug resistance |
|
Protozoan Infections Anti-Infective Agents Antiprotozoal Agents Coccidiosis Chloroquine Malaria Pharmacologic Actions |
Antimalarials Antiparasitic Agents Therapeutic Uses Parasitic Diseases Amebicides Antirheumatic Agents |
